Scarica l'app Stockscreener
4.945
0.41%
0.015
Precedente Chiudi:
$4.93
Aprire:
$4.94
Volume 24 ore:
402.44K
Relative Volume:
0.23
Capitalizzazione di mercato:
$476.17M
Reddito:
-
Utile/perdita netta:
$-81.49M
Rapporto P/E:
-6.1125
EPS:
-0.809
Flusso di cassa netto:
$-73.48M
1 W Prestazione:
-4.81%
1M Prestazione:
+16.47%
6M Prestazione:
+110.64%
1 anno Prestazione:
-0.60%
Intervallo 1D:
$4.71
$4.965
Intervallo di 1 settimana:
$4.71
$5.42
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.945 | 472.80M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
524.57 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.15 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.04 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.17 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.09 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
RZLTRezolute Inc Options - Finviz
RZLT News | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Price to earnings forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to book forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to earnings forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to revenue forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Enterprise value to revenue forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to EBITDA forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to EBIT forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to sales forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Enterprise value to EBIT forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Price to sales forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Rezolute, Inc. Actuals & Estimates (NASDAQ:RZLT) - TradingView
RZLT Forecast — Price Target — Prediction for 2027 - TradingView
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute Inc (RZLT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RZLT stock plummets 79% month to date: Here's what you need to know - MSN
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth - Streetwise Reports
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data - Streetwise Reports
Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rezolute data: 75% of tumor HI patients came off IV dextrose at ENDO - Stock Titan
Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rezolute Inc (RZLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rezolute Inc (RZLT) Institutional Confidence - TradingKey
Rezolute presents hyperinsulinism data at endocrine meeting - Investing.com UK
Rezolute presents hyperinsulinism data at endocrine meeting By Investing.com - Investing.com South Africa
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society - The Manila Times
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug ... - Caledonian Record
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rezolute Inc (RZLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rezolute Inc (RZLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
RZLT Maintained by Guggenheim -- Price Target Raised to $11.00 - GuruFocus
Rezolute Price Target Raised to $11.00/Share From $6.00 by Guggenheim - Moomoo
Guggenheim raises Rezolute stock price target on trial outlook - Investing.com UK
Guggenheim raises Rezolute stock price target on trial outlook By Investing.com - Investing.com Canada
Guggenheim Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Exploring 3 High Growth Tech Stocks in US Market - simplywall.st
RZLT stock on the move: What sparks the 38% jump in the past week? - MSN
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL) - The Globe and Mail
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance
RZLT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Cautious OutlookDiluted EPS Report - newsline.com
Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT) - The Globe and Mail
RZLT: Strong interim efficacy in tumor HI and key regulatory milestones expected later this year - TradingView
RZLT: Strong interim efficacy in tumor HI and regulatory clarity for congenital HI expected this year - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - The Globe and Mail
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society - The Manila Times
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism - Quiver Quantitative
Rezolute (RZLT) Receives a Buy from Guggenheim - The Globe and Mail
Phase 3 congenital hyperinsulinism study results to be shared at ENDO 2026 - Stock Titan
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):